Furthermore, we suggest that targeting the pathway of CD38-induced ADO formation may serve as a promising therapeutic approach, with diverse effects on mature B-cell neoplasms, including interactions with the PD-1/PD-L1 axis and the management of associated conditions such as thrombocytopenia and anemia. This evidence concerns the gene CD38 and B-cell neoplasm.